



PRESS RELEASE

ProBioGen AG is the fastest growing life sciences company in Deloitte's Technology Fast 50 ranking

With a cumulative revenue increase of more than 1,100 % over the past five years, the Berlin-based biotech company reaches rank 13 on this year's Deloitte list of the fastest growing German technology companies

Berlin, 11th October 2007 – As part of the award ceremony for the '*Deloitte Technology Fast 50 Award*', this year's fastest growing German technology companies were announced yesterday evening in Frankfurt am Main. The rankings were based on the cumulative revenue increase over the past five years. ProBioGen AG achieved a growth of 1,118 % during this period, thereby positioning themselves on rank 13 among all participating German technology companies. ProBioGen is the fastest growing life science company on this year's list.

The *Technology Fast 50 Award* sponsored by Deloitte was presented for the fifth year in a row in 2007. Among more than 300 participating German technology companies from the IT, communications, renewable energy and life sciences sectors, the 50 fastest growing companies were honored for their commercial accomplishments.

"We owe this excellent ranking to our highly committed employees as well as our products and services which are exactly tailored to the needs of our customers," Michael Schlenk, CEO of ProBioGen comments. "We are internationally renowned for our expertise in the development of cell lines used to produce highly specific and innovative pharmaceutical products. Based on these capabilities, we were able to expand our customer base during the past years through our outstanding service performance. In addition, we develop and market our own products to ensure continued value creation in the future."

About ProBioGen AG

ProBioGen is a specialist for cell line design, viral vectors, and the manufacture of glycoproteins for the biopharmaceutical industry. The German biotechnology company is headquartered in Berlin. Its range of products and services include the development of highly productive cell lines, the design of novel cell lines from primary tissue, the manufacture of glycoproteins for clinical studies and R&D, as well as the production of viral vectors and antibodies for in vitro diagnostics. ProBioGen possesses the manufacturing authorization for pharmaceutically usable active substances for testing in clinical studies and meets the quality standards recommended by the EU (EMA) and the FDA. A certified cGMP multipurpose facility is available for contract production of biopharmaceutical active substances. The Company is specialized in mammalian cells and combines the know-how of molecular biology scientists with the experience of experts in cell culture technology and process engineering. ProBioGen thus accompanies its clients from the early development of product candidates up to late clinical testing phase.

About Deloitte Germany

Deloitte is one of the leading auditing and consulting firms in Germany. The company's broad service spectrum includes auditing, tax accounting, consulting and corporate finance consulting. 3,400 employees in 18 branch offices serve companies and institutions of any size and legal form in all sector of industry for over 100 years. Deloitte is represented via the Deloitte Touche Tohmatsu network with 150,000 employees in nearly 140 countries world-wide.

ProBioGen Contact

Michael Schlenk, CEO
Goethestrasse 54
13086 Berlin
Tel.: +49. (0)30. 924 006-0
Fax: +49. (0)30. 924 006-19
email: michael.schlenk@probiogen.de